SAREPTA THERAPEUTICS, INC. Lease, Cost
SAREPTA THERAPEUTICS, INC. (SRPT) reported Lease, Cost of $146.39 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:LeaseCost · last filed 2026-03-02
- SAREPTA THERAPEUTICS, INC. lease, cost for the quarter ending 2019-12-31 was $3.62M.
- SAREPTA THERAPEUTICS, INC. lease, cost for the quarter ending 2019-09-30 was $3.61M.
- SAREPTA THERAPEUTICS, INC. lease, cost for the quarter ending 2019-06-30 was $3.34M.
- SAREPTA THERAPEUTICS, INC. lease, cost for the quarter ending 2019-03-31 was $3.73M.
- SAREPTA THERAPEUTICS, INC. lease, cost for fiscal 2025 was $146.39M, a 41.24% increase from fiscal 2024.
- SAREPTA THERAPEUTICS, INC. lease, cost for fiscal 2024 was $103.64M, a 51.67% increase from fiscal 2023.
- SAREPTA THERAPEUTICS, INC. lease, cost for fiscal 2023 was $68.34M, a 27.28% increase from fiscal 2022.
- SAREPTA THERAPEUTICS, INC. lease, cost for fiscal 2022 was $53.69M, a 13.08% increase from fiscal 2021.
| Period end | Lease, Cost 3 month | Lease, Cost 6 month | Lease, Cost 9 month | Lease, Cost 12 month |
|---|---|---|---|---|
| 2025-12-31 | $146.39M 10-K · filed 2026-03-02 | |||
| 2024-12-31 | $103.64M 10-K · filed 2026-03-02 | |||
| 2023-12-31 | $68.34M 10-K · filed 2025-02-28 | |||
| 2022-12-31 | $53.69M 10-K · filed 2024-02-28 | |||
| 2021-12-31 | $47.48M 10-K · filed 2023-02-28 | |||
| 2020-12-31 | $36.04M 10-K · filed 2022-03-01 | |||
| 2019-12-31 | $3.62M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-26 | $7.23M derived: sum of 2 quarters · filed 2020-02-26 | $10.57M derived: sum of 3 quarters · filed 2020-02-26 | $14.30M 10-K · filed 2020-02-26 |
| 2019-09-30 | $3.61M 10-Q · filed 2019-11-07 | $6.95M derived: sum of 2 quarters · filed 2019-11-07 | $10.68M 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $3.34M 10-Q · filed 2019-08-07 | $7.07M 10-Q · filed 2019-08-07 | ||
| 2019-03-31 | $3.73M 10-Q · filed 2019-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |